| Long name: |
FITC Conjugated, Complement C3 Polyclonal Antibody |
| Category: |
Conjugated Primary Antibodies |
| Conjugation: |
Anti-FITC Antibody |
| Host Organism: |
Rabbit (Oryctolagus cuniculus) |
| Target Antigen: |
Complement C3 |
| Specificity: |
This is a highly specific antibody against Complement C3 |
| Modification: |
Unmodified |
| Modification site: |
None |
| Clonality: |
Polyclonal |
| Clone: |
Polyclonal antibody |
| Concentration: |
1ug per 1ul |
| Immunogen_range: |
1611-1631/1663 |
| Subcellular location: |
Secreted |
| Source: |
KLH conjugated synthetic peptide derived from human Complement C3 alpha chain |
| Gene ID number: |
718 |
| Swiss Prot: |
P01024 |
| Tested applications: |
IF(IHC-F), IF(IHC-P) |
| Recommended dilutions: |
IF(IHC-F)(1:50-200), IF(IHC-P)(1:50-200) |
| Crossreactivity: |
Bovine, Mouse, Rat, Human |
| Crossreactive species details: |
not every possible cross-reactivity is known, Due to limited amount of testing and knowledge |
| Antigen background: |
ARRB2-mediated internalization and recycling of C5AR2 (PubMed:837664, Acylation stimulating protein: adipogenic hormone that stimulates triglyceride (TG) synthesis and glucose transport in adipocytes, After activation C3b can bind covalently, Appears to stimulate TG synthesis via activation of the PLC, C3-beta-c: Acts as a chemoattractant for neutrophils in chronic inflammation, C3a anaphylatoxin is a mediator of local inflammatory process, Derived from proteolytic degradation of complement C3, In chronic inflammation, It induces the contraction of smooth muscle, Its processing by C3 convertase is the central reaction in both classical and alternative complement pathways, Ligand for C5AR2, MAPK and AKT signaling pathways, Promotes the phosphorylation, PubMed:1432298, PubMed:15833747, PubMed:16333141, PubMed:1961575), PubMed:29953, PubMed:959512, acts as a chemoattractant for neutrophils (By similarity), increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes, regulating fat storage and playing a role in postprandial TG clearance, to cell surface carbohydrates or immune aggregates, via its reactive thioester, C3 plays a central role in the activation of the complement system |
| Purification method: |
This antibody was purified via Protein A |
| Storage conditions: |
50% glycerol and 0, Store refrigerated at 2 to 8 degrees Celcius for up to 1 year, 09% sodium azide, Keep the antibody in an aqueous buffered solution containing 1% BSA |
| Excitation Emission: |
494nm/518nm |
| Synonyms: |
AHUS5, ARMD9, C3, C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1, C3a, C3b, CPAMD1, Complement C3, HEL-S-62p, ASP |
| Properties: |
Bioss Primary Conjugated Antibodies FITC is highly sensitive to pH extremes, FITC has a green emission that's usually collected at 530 nanometers, FITC has a high quantum yield (efficiency of energy transfer from absorption to emission fluorescence) and approximately half of the absorbed photons are emitted as fluorescent light, For fluorescent microscopy applications, This Bioss Primary Conjugated Antibodies Fluorescein isothiocyanate (FITC) antibody is currently after some BD antibodies the most commonly used fluorescent dye for FACS, When excited at 488 nanometers, its photo bleaching effects are not observed due to a very brief interaction at the laser intercept, the 1 FITC is seldom used as it photo bleaches rather quickly though in flow cytometry applications, the FL1 detector of a FACSCalibur or FACScan, C, C for long term storage and for short term at + 5°, If you buy Antibodies supplied by Bioss Primary Conjugated Antibodies they should be stored frozen at - 24° |
| Gene target: |
Complement C3 Conjugated |
| Short name: |
FITC Conjugated, Complement C3 Antibody |
| Technique: |
Fluorescein, antibodies against human proteins, antibodies for, antibody Conjugates, Antibody |
| Label: |
FITC |
| Alternative name: |
fluorecein coupled, Complement complement component 3 (Antibody to) |
| Alternative technique: |
antibodies |
| Alternative to gene target: |
AHUS5 and ARMD9 and ASP and C3a and C3b and CPAMD1 and HEL-S-62p, BT, C3 and IDBG-193788 and ENSMUSG00000024164 and 102642251, C3 and IDBG-21798 and ENSG00000125730 and 718, C5L2 anaphylatoxin chemotactic receptor binding, Extracellular, alternative pathway and biological process this GO :0006958 and complement activation, classical pathway and biological process this GO :0007165 and signal transduction and biological process this GO :0007186 and G-protein coupled receptor signaling pathway and biological process this GO :0010575 and positive regulation vascular endothelial growth factor production and biological process this GO :0010828 and positive regulation of glucose transport and biological process this GO :0010866 and regulation of triglyceride biosynthetic process and biological process this GO :0010884 and positive regulation of lipid storage and biological process this GO :0010951 and negative regulation of endopeptidase activity and biological process this GO :0030449 and regulation of complement activation and biological process this GO :0031715 and C5L2 anaphylatoxin chemotactic receptor binding and molecular function this GO :0045087 and innate immune response and biological process this GO :0045745 and positive regulation of G-protein coupled receptor protein signaling pathway and biological process this GO :0045766 and positive regulation of angiogenesis and biological process this GO :0050766 and positive regulation of pha this GO cytosis and biological process this GO :0050776 and regulation of immune response and biological process this GO :0070062 and extracellular vesicular exosome and cellular component this GO :0072562 and blood microparticle and cellular component this GO :2000427 and positive regulation of apoptotic cell clearance and biological process, this GO :0001798 and positive regulation of type IIa hypersensitivity and biological process this GO :0001934 and positive regulation of protein phosphorylation and biological process this GO :0001970 and positive regulation of activation of membrane attack complex and biological process this GO :0004866 and endopeptidase inhibitor activity and molecular function this GO :0005102 and receptor binding and molecular function this GO :0005515 and protein binding and molecular function this GO :0005576 and extracellular region and cellular component this GO :0005615 and extracellular space and cellular component this GO :0005886 and plasma membrane and cellular component this GO :0006631 and fatty acid metabolic process and biological process this GO :0006954 and inflammatory response and biological process this GO :0006955 and immune response and biological process this GO :0006956 and complement activation and biological process this GO :0006957 and complement activation, this GO :0004866 : endopeptidase inhibitor activity, this GO :0004866 : endopeptidase inhibitor activity and also this GO :0005102 : receptor binding and also this GO :0005515 : protein binding and also this GO :0031715 : C5L2 anaphylatoxin chemotactic receptor binding, this GO :0005102 : receptor binding, this GO :0005515 : protein binding, this GO :0031715 : C5L2 anaphylatoxin chemotactic receptor binding, 12266, 19562 and IDBG-643930 and ENSBTAG00000017280 and 280677, complement component 3 |